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Summary
Identification of a biocompatible immunoprotective membrane
to prevent graft rejection remained elusive until the develop-
ment of microcapsules formulated in alginate. We report in vit -
ro parathyroid hormone secretion from encapsulated human
parathyroid tissue using a highly biocompatible alginate pro-
duced under GMP conditions. The in vitro function of human
parathyroid tissue fragments was maintained after 8 days of
culture of alginate microcapsules in serum-free conditions.
The structural features of parathyroid tissue was maintained in
these culture conditions. Using a biopolymer of clinical grade
may be a crucial step toward a clinical use of this technique in
parathyroid allotransplantion without immunosuppression.
KEY WORDS: parathyroid tissue, parathyroid cells, hypoparathyroidism, al -
ginate, cell therapies.
Introduction
Attempts to transplant parathyroid glands began almost a cen-
tury ago, only two decades after the organ had been discov-
ered, with the demonstration by histologic means that canine
parathyroid autografts survived (1). Graft function was as-
sessed only fifty years later, with the demonstration that
parathyroid transplanted tissue in rodents functions sufficiently
to maintain the host in a normocalcemic state (2). However,
parathyroid allografts were successful only in immunosup-
pressed canine and human recipients (3,4).
Indications for parathyroid allotransplantation are rare, as hy-
poparathyroid patients who cannot be controlled on a medical
regimen are also unusual. In these subjects the symptoms and
associated complications of hypoparathyroidism cannot be
controlled sufficiently with oral calcium and vitamin D. Due to
these problems, alternate treatment modalities, involving more
physiological and longer-acting systems for parathyroid hor-
mone (PTH) delivery, needs to be pursued.
Various methods of immunomanipulation have been proposed
to overcome allograft rejection, which include immunosuppres-
sion, immunomodulation and immunoisolation. By using the im-
munoisolation concept the transplant is enclosed in a biocom-
patible material to immobilize the transplant and at the same
time preventing an immune response of the recipient. In 1964,
T.M.S. Chang proposed the idea of using ultrathin polymer
membrane microcapsules for the immunoprotection of trans-
planted tissues and cells (5). When implanted into rats, the mi-
croencapsulated pancreatic islets corrected the diabetic state
for several weeks (6). Since then, bioencapsulation has provid-
ed a range of promising therapeutic treatments for diabetes,
hemophilia, cancer and renal failure (7-10). In addition, the ap-
plicability of cell encapsulation in humans has also been report-
ed in several clinical trials (11,12). Indeed, cell encapsulation in
biocompatible and semipermeable polymeric membranes has
been an effective method for immunoprotection, regardless of
the type of recipient (13), as encapsulated cells can maintain
their viability while allowing for the secretion of desired thera-
peutic agents, either continuously or in response to specific
physiologic stimulations.
Also for the treatment of refractory hypoparathyroidism, im-
munoisolated allogeneic transplantation of parathyroid tissue is
regarded as a promising therapy concept (14), which has been
successfully applied in iso-, allo-, and xeno-transplantations in
animals by using purified alginates (15-17). Alternatively, isolat-
ed parathyroid cells are under investigation (18,19).
Up to now, a substantial challenge has been the lack of clinical
grade polymers and the demanding task is to accomplish spe-
cific material requirements of high quality standards. By using
homogeneous raw material and a standardized purification pro-
tocol a new class of clinical grade biopolymers was developed
which establish the basis for the clinical application of encapsu-
lation technology (20). The batches of the purified alginate
have to be standardized as for the endotoxin, protein and phe-
nolic content and also for the physical properties such as the
distribution of the molar mass and the viscosity.
In the present study, we report in vitro data for the use of clini-
cally suitable alginate-encapsulated human parathyroid tissue
microspheres as a novel allo- and xeno-transplantation method
for the delivery of PTH.
Materials and methods
Quality control of the biopolymer and cytotoxicity testing
Three different batches (a-c) of biocompatible alginate isolated
from freshly collected Laminaria pallida (20) were tested in
eight replicates, using three different cell lines (mouse, ape,
uman): L-929 (DSMZ # ACC 2), VERO-B4 (DSMZ ACC # 33)
and NHDF (CellSystems, St. Katharinen, Germany). Experi-
ments were repeated five times.
For cytotoxicity tests 100 ml of cell suspensions were plated at
a density of 2x105 cells/ml in 96-well plates. Cells were incu-
bated overnight in an incubator at 37°C in 5% CO2/95% air hu-
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midified atmosphere. A 0.1% (w/v) suspension of the biopoly-
mer was prepared in cell culture medium (RPMI 1640, supple-
mented with 2 mM L-glutamine and 10% fetal calf serum). Cul-
ture medium was used as negative control and CuSO4 ( 5 0
ng/ml) in culture medium was used as positive control. Biopoly-
mer suspension and control media were mixed overnight on an
overhead shaker at room temperature. Cultured cells were
checked for confluency and morphology after 24-hr incubation,
when cell culture medium was removed and replaced by 100
m L of the biopolymer suspension. Positive and negative con-
trols were tested in every dish. Cells were incubated for three
days in the incubator. At day three 25 m L of Alamar-Blue solu-
tion (Biozol, Echingen, Germany) were added to each well and
incubated. Fluorescence (excitation wavelength 535 nm, emis-
sion wavelength 590 nm) was measured after three hours.
Metabolic activity of the cells was calculated versus baseline
(negative controls) and expressed as percent difference.
Culture and encapsulation of human parathyroid tissue
Fresh human parathyroid tissue was obtained from six different
patients undergoing surgery for parathyroid hyperplasia due to
secondary hyperparathyroidism. Parathyroid tissue was trans-
ported to the laboratory under sterile conditions and then cut in-
to fragments of about 2 mm3. Tissue particles were then kept ei-
ther in RPMI 1640 medium supplemented with 2 mM L-gluta-
mine and 10% AB-serum (17) or in serum-free culture medium
in the incubator for three days with daily changes of culture
medium. Thereafter, tissue particles were microencapsulated
using the CellBeads® Biopolymer, produced according to GMP
requirements (CellMed AG, Alzenau, Germany), through sus-
pension in the biopolymer solution. The solution was passed
through a spray nozzle and the resulting microcapsules were
transferred into culture medium and further cultured for 10 days.
In vitro release of PTH from human encapsulated parathyroid
tissue
Intact PTH release was daily measured during a period varying
from seven to eight days. For the measurement of PTH release
five microcapsules were transferred into 5 mL of fresh serum-
free medium and incubated for two hours, when 500 m l of the
supernatant were removed and immediately frozen at –20°C.
After thawing human PTH 1-84 concentrations were measured
by an ELISA method (DSL, Webster, USA) and the median
PTH release of one capsule was derived.
Hematoxylin-eosin staining
At day seven encapsulated tissue particles were fixed in 4%
formalin, Hematoxylin-Eosin (H&E) stained and histologically
analyzed.
Results
Quality control of the biopolymer and cytotoxicity testing
The biopolymer used in this investigation expressed a whole
set of quality control measures as it is produced under GMP
conditions. The biopolymer was highly biocompatible, as
demonstrated in vitro and in vivo (20). For each lot a whole set
of quality controls was routinely performed, such as cytotoxicity
testing in three different batches of the biopolymer using three
different cell lines of diverse origin. No cytotoxic effect was ob-
served for three different batches of the biopolymer using the
three different cell lines (Fig. 1).
In vitro release of PTH from human encapsulated parathyroid
tissue
The median intact PTH release per microcapsule was calculat-
ed over two hour period of incubation in serum-free medium
using parathyroid tissue obtained from three different patients.
At day one PTH release was below 500 pg/mL for all tissues
with a constant increase in the following days (Fig. 2).
Histological examination
Microencapsulated human parathyroid tissue showed an excel-
lent viability over 7/8 days in culture (Fig. 3).
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Figure 1. Cytotoxicity testing was performed for three biopolymer solutions (a-c) using three different cell lines (L-929, VERO, and NHDF). The meta-
bolic activity of the cell lines is expressed as percentage on negative controls. The positive control (pos. control) is represented by RPMI 1640 culture
medium containing 50 ng/mL CuSO4.
Figure 2 - PTH release from encapsulated human parathyroid tissue
fragments obtained from three different donors. Intact PTH release over
2 hours of incubation in serum-free medium was evaluated for a period
up to 8 days. The mean intact PTH release was elaborated from the re-
lease from 10 microcapsules and expressed as pg/2hr/capsule.
serum free culture medium
time [d]
a b C pos. control a b c pos. control a b alginate C pos. control
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Discussion
Secondary hypoparathyroidism with permanent hypocalcemia
is a well recognized complication after thyroid surgery, reach-
ing up to 30% after total thyroidectomy (21, 22). More rarely,
hypoparathyroidism can occur as a congenital primary disor-
der, characterized by genetic heterogeneity (23,24). Perma-
nent hypoparathyroidism is one of the most difficult of all en-
docrine disorders to treat medically. This is particularly true for
subjects who do not respond to medical therapy with calcium
and vitamin D3 (refractory hypoparathyroidism) (25). As organ
transplantation is an option for permanent organ dysfunction,
the need for parathyroid allotransplantation could be justified.
Because hypoparathyroidism rarely is vital threat to the patient,
systemic post-transplant immunosuppression is not justified.
The applicability of bioencapsulation to immunoisolate parathy-
roid tissue or cells has provided a range of encouraging results
in in vitro and in vivo experimental models (14-19).
While a large number of synthetic, semi-synthetic and natural
water soluble polymers have been evaluated as potential mate-
rials for cell and tissue encapsulation (26, 27), the most
promising approach are hydrogel- and particularly alginate-
based microcapsules, as these materials meet best the re-
quirements for long-term immunoisolation and simultaneous
maintenance of transplant function (28). However, a consistent
and standardized quality of the material which is a pre-requisite
for biomedical applications has not been provided so far. Other
challenges involve the production of uniform capsules through
automated machines, the suitability of cell or tissue types for
immobilization, and the transplantation site. For all these rea-
sons allotransplantation of parathyroid tissue is still in its exper-
imental stage, with the exception of isolated attempts in hu-
mans (15, 29). Moreover, the variability of the materials used in
different investigations accounts for the poor comparability of
results.
In a stepwise analysis of the essential obstacles, we have de-
veloped a clinical grade biomaterial. Indeed, the purified
biopolymer used in this investigation was produced under GMP
conditions, encompassing several quality control measures,
such as cytotoxicity testing. This material made possible thein
vitro maintenance of both morphological and functional fea-
tures of human parathyroid tissue, as shown through histologi-
cal examination and measurement of PTH release. In addition,
the lack of need for fetal calf serum in the culture medium is
another interesting characteristic of our microencapsulation
model, because potential sources for disease transmission,
such as additives of animal or human origin, could be avoided.
The results of this study, together with those of previous in vivo
studies using amitogenic alginate (16) provided the rationale
needed for the clinical application of encapsulation technology
in the treatment of hypoparathyroid patients refractory to med-
ical therapy. The use of parathyroid cell suspension may pro-
vide an additional opportunity to further improve this therapy
ption.
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Figure 3 - Histological sections of encapsulated human parathyroid fragments. H&E staining showed a conserved morphology after 7 days in culture
with serum-free culture medium.
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